Stock AnalizNuvation Bio Inc. NUVB
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Nuvation Bio Inc. (NUVB) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $202M and net income of -$136M, a net margin of -67.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -46%.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $202M | $63M | $8M | $0 | — | — | — |
| Net income | -$136M | -$205M | -$568M | -$76M | -$104M | -$87M | -$42M |
| Free cash flow | -$108M | -$181M | -$130M | — | — | — | — |
| EPS (diluted) | $-0.40 | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 | $-0.43 |
| Net margin | -67.4% | -325.3% | -7213.8% | — | — | — | — |
| ROIC | — | -58.7% | -125.4% | -16.4% | -18.2% | -12.5% | -19.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $12.45, 212% above the current price; targets range from $7.00 to $21.00; the consensus rating is “Strong buy”; expected EPS is $-0.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Nuvation Bio pay a dividend?
Not currently.
Is Nuvation Bio a good stock to buy?
We do not give buy or sell advice. Nuvation Bio scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.